UK Regulators Approve FLAMINGO-01 Expansion, Adding 5-10 Sites
GLSI sits 88% above its 52-week low of $7.78 on elevated volume (2.1× avg).
Summary
UK regulators approved the expansion of the Phase III FLAMINGO-01 trial into the United Kingdom, adding 5-10 sites to the existing 170-180 in the US and Europe. The company is collaborating with The Royal Marsden, a top cancer center, whose principal investigator will join the trial's Steering Committee. This follows the July 9 European approval to use commercially manufactured GP2 and the July 16 EMA approval to combine patient arms, showing steady regulatory progress. The UK expansion taps a population of 70 million and approximately 59,400 new breast cancer cases annually, potentially accelerating enrollment. With a going concern warning and rising cash burn, faster trial completion is critical for the company's runway.
At the time of this announcement, GLSI was trading at $14.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $215M. The 52-week trading range was $7.78 to $34.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.